United States: The Supreme Court Delivers A Win For Biosimilar Manufacturers In Sandoz v. Amgen

On June 12, 2017, the Supreme Court issued a unanimous opinion in Sandoz v. Amgen, interpreting key provisions of the Biologics Price Competition and Innovation Act (BPCIA) in favor of biosimilar manufacturers (applicants).1 In particular, the Court held that (1) a federal injunction is not available to compel biosimilar applicants to disclose application and manufacturing information as contemplated by the BPCIA, and (2) biosimilar applicants may provide statutory 180-day notice of commercial marketing after or before receiving FDA approval.

The BPCIA "patent dance"

The BPCIA was approved by Congress in 2010 for the purpose of creating an abbreviated approval pathway for biosimilars, or follow-on biologics. In contrast to conventional chemically synthesized drugs, biologics are isolated from natural sources such as animals or microorganisms and may include such diverse products as vaccines, recombinant proteins or somatic cells.2 Biosimilar manufacturers may take advantage of the BPCIA's abbreviated approval pathway to piggyback on the safety, purity and potency showings of a previously licensed reference product. In exchange, the BPCIA allows for up to 12 years of regulatory exclusivity for the reference product after the date the product was first licensed, regardless of whether there is patent protection. 

Broadly speaking, the BPCIA establishes an elaborate exchange of information relating to patent disputes, triggered by the submission of an abbreviated biologics license application (aBLA) to the Food and Drug Administration (FDA).3 However, the so-called "patent dance" under the BPCIA has been criticized for being overly complex and was famously characterized by the Federal Circuit as "a riddle wrapped in a mystery inside an enigma."4

The dispute

The dispute between Amgen and Sandoz concerns the biologic filgrastim, a recombinant DNA product indicated for treating side effects of certain forms of cancer therapy. Amgen has marketed filgrastim under the trade name Neupogen since 1991. Sandoz, a biosimilar manufacturer, sought permission to market a biosimilar filgrastim product with the brand name Zarxio, naming Neupogen as the reference product. Instead of complying with the preliminary exchanges as detailed under the BPCIA and providing Amgen with its commercial manufacturing information, Sandoz submitted an application to the FDA and notified Amgen that it planned to market Zarxio immediately upon receiving FDA approval.

The lower court decisions

Amgen sued Sandoz in the United States District Court for the Northern District of California for patent infringement and for state law claims of unfair competition and conversion. Amgen sought injunctions to compel Sandoz to comply with the BPCIA provisions as well as for restitution, attorney's fees, costs and expenses. Sandoz counterclaimed, seeking declaratory judgment of noninfringement and invalidity, and further seeking declaratory judgment that it correctly interpreted its obligations under the BPCIA.

The district court granted partial judgment on the pleadings, (1) dismissing with prejudice Amgen's state law claims of unfair competition and conversion, (2) granting judgment on the pleadings to Sandoz on its counterclaim for a declaratory judgment that it correctly interpreted the BPCIA and (3) denying Amgen's motion for preliminary injunction based on its state law claims.5 Amgen appealed to the Federal Circuit, which granted an injunction against commercial marketing of Zarxio® pending appeal.

The Federal Circuit affirmed in part, vacated in part and remanded. The Federal Circuit determined that applicants may opt out of the BPCIA, interpreting the BPCIA's mandate that an applicant "shall provide" application and manufacturing process information within 20 days after acceptance of applicant's aBLA6 to mean that the applicant is required to disclose the information only if it avails itself of the BPCIA. Failure to disclose the required information is an act of infringement under 35 U.S.C. §271(e), and the manufacturers of the biological reference product (sponsors) may sue for patent infringement and access the information through discovery. In the same opinion, the Federal Circuit favored sponsors by interpreting 42 U.S.C. § 262(l)(8)(A) to require that an applicant give notice of commercial marketing after the FDA licenses the product, which may result in an extra 180 days of exclusivity for the sponsor.

The Supreme Court granted Sandoz's petition for certiorari and Amgen's conditional cross-petition for certiorari.

The Supreme Court's decision

A. Federal injunctions are not available to enforce compliance with the BPCIA's information disclosure requirements

The Supreme Court first considered what recourses are available to the sponsor when an applicant fails to provide the sponsor with its application and manufacturing information as required by §262(l)(2)(A). Agreeing with the Federal Circuit's conclusion, though not its reasoning, the Court determined that an injunction under federal law is not available to enforce §262(l)(2)(A). In particular, the Court determined that the Federal Circuit erred in reasoning that failing to disclose the required information is an act of artificial infringement under §271(e)(4). Instead, the Court held that a sponsor is entitled to bring a declaratory judgment action for artificial infringement under §271(e)(2)(C)(ii), thereby depriving the applicant of the opportunity to bring a declaratory judgment action prior to marketing. The Court remanded for a determination as to whether an injunction is available under state law, leaving open the question of whether failing to comply with the BPCIA is "unlawful" under California's unfair competition law. The Federal Circuit is also charged with determining whether the BPCIA preempts any additional state law remedy for failure to comply with §262(l)(2)(A).

B. Applicants may give notice of commercial marketing before licensure

Next, the Supreme Court considered whether 42 U.S.C. § 262(l)(8)(A) requires the applicant to provide the sponsor with 180 days' notice of commercial marketing after licensure but before it begins marketing its biosimilar product. The Court held that the applicant may elect to give "notice" at least 180 days before the date of first commercial marketing. In so holding, the Court interpreted the statute merely to require that a product be licensed at the time it is commercially marketed, not that a product be licensed at the time notice is given. The Court noted that both sides presented "a host" of policy arguments in favor of or against prelicensure notice, but concluded that even the most persuasive policy arguments could not overcome the "plain language" of the statute.

The holding is a blow to biologics manufacturers, which stood to benefit from the extra 180 days of exclusivity that might result if the applicant were prevented from providing notice of commercial marketing until after receiving FDA approval. Some biologic products generate revenues in the billions of dollars a year, so an extra 180 days of market exclusivity might translate into hundreds of millions of dollars in additional revenue.

Overall, the Court's decision favors biosimilar applicants by allowing them considerable flexibility in choosing how and when to address patent disputes. In situations where branded biologic products have already lost the 12 years of regulatory exclusivity provided for by the BPCIA, biosimilar applicants may choose to bypass the BPCIA altogether. The patent dance could last more than two years before a patent infringement suit is filed, making bypassing the BPCIA in favor of litigating the patents quickly an attractive alternative that could allow biosimilars to reach the market sooner. However, for those products that are still within the 12-year exclusivity period, the Court's determination that applicants may provide notice of commercial marketing before licensure may incentivize applicants to take advantage of the BPCIA to resolve all patent disputes before the expiration of the regulatory exclusivity period. Even traditional branded pharmaceutical companies have recognized the value of biosimilar products, and many, including Amgen, have biosimilar products in the pipeline.


1 Sandoz Inc. v. Amgen Inc., No. 15-1039, 2017 WL 2507337 (U.S. June 12, 2017).

2 See FDA, What Are "Biologics" Questions and Answers (Aug. 5, 2015), http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cber/ucm13307.htm.

3 42 U.S.C § 262(l).

4 Amgen Inc. v. Sandoz Inc., 794 F.3d 1347, 1351 (Fed. Cir. 2015), cert. granted, 137 S. Ct. 808 (2017), and cert. granted, 137 S. Ct. 808, 196 L. Ed. 2d 594 (2017), and rev'd in part, vacated in part, No. 15-1039, 2017 WL 2507337 (U.S. June 12, 2017).

5 Amgen Inc. v. Sandoz Inc., No. 14-cv-04741, 2015 WL 1264756 (N.D. Cal. Mar. 19, 2015).

6 42 U.S.C. § 262(l)(2)(A)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.